万东医疗: 万东医疗关于以集中竞价交易方式回购股份方案的公告

Core Viewpoint - The company plans to repurchase shares through a centralized bidding process, with a total amount ranging from RMB 30 million to 60 million, aimed at employee stock ownership plans or equity incentives [1][2][4]. Summary by Sections Repurchase Plan Overview - The repurchase amount is set between RMB 30 million and 60 million [1][2]. - The funding source for the repurchase will be the company's own funds [1][5]. - The maximum repurchase price is capped at RMB 25 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4]. - The repurchase will be conducted via centralized bidding [1][3]. - The duration for the repurchase is 12 months from the board's approval [1][3]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for employee stock ownership plans or equity incentives [1][3][4]. - If the shares are not fully utilized for these purposes within three years, the company will follow the necessary procedures to cancel the unused shares and reduce registered capital accordingly [4][5]. Implementation and Conditions - The repurchase plan requires approval from at least two-thirds of the board members and does not need to be submitted to the shareholders' meeting [2][3]. - The estimated number of shares to be repurchased is between 120,000 and 240,000, representing 0.17% to 0.34% of the total share capital [2][4]. - The company will adjust the repurchase price if there are any capital changes, such as stock splits or dividends [4][5]. Financial Impact - The total amount for the repurchase represents approximately 1.10% of the company's total assets and 1.26% of the equity attributable to the parent company [5]. - The company asserts that the repurchase will not significantly impact its daily operations, financial status, research and development, profitability, or debt servicing capabilities [5][6]. Management and Compliance - The board has authorized the management to handle all matters related to the repurchase, including adjustments based on market conditions [7]. - There are no current plans for share reduction by directors, senior management, or major shareholders in the next three to six months [6][8].